Switch from tenofovir DF to raltegravir is not associated with weight gain over 96 weeks.
Sign Up to like & getrecommendations! Published in 2019 at "AIDS"
DOI: 10.1097/qad.0000000000002473
Abstract: : Integrase inhibitor-based antiretroviral therapy (INSTI-ART) can cause weight gain. It is unknown if this is a class effect, with limited data regarding raltegravir. In 37 virologically suppressed adults (36 men, mean age 49 years)… read more here.
Keywords: raltegravir associated; tenofovir raltegravir; raltegravir; weight gain ... See more keywords
A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of offâtherapy relapse: An observational study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.15966
Abstract: In HBeAg negative chronic hepatitis B (CHB) patients, clinical relapse (CR) occurs more frequently, much earlier and often more severely after stopping tenofovir (TDF) and other nucleos(t)ide analogues (Nucs) than after stopping entecavir (ETV). It… read more here.
Keywords: relapse; tenofovir entecavir; switch tenofovir; hepatitis ... See more keywords